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Abstract
In recent years, breast cancer (BC) is the most common cancer pathology and the most common cause of disability among 
women in developed countries. Finding the most effective ways of interaction between the patient and the doctor creates the precon-
ditions for the necessary analysis of the treatment process from an objective and subjective point of view. Therefore, an important 
indicator to be taken into account is the quality of life of a patient.
To compare the indicators of a comprehensive assessment of the quality of life of patients to the adverse locally advanced 
forms (LA) of breast cancer before and after systemic intravenous polychemotherapy (SPCTx) and selective endolymphatic polyche-
motherapy (ELPCTx) in neoadjuvant mode.
The study was conducted on the basis of a random analysis of outpatient cards from 112 patients with LA BC T4A-DN0-3M0 
who received a comprehensive antitumor treatment on the basis of the Donetsk regional antitumor center and the University Clinic 
of the Odessa National Medical University from 2000 to 2017, which was proposed a questionnaire at various stages of preoperative 
treatment. The first (control) group consisted of 65 patients (58 %) with inoperable forms of LA BC, which was performed in neoad-
juvant mode by SPCTx. The second (study group) included 47 patients (42 %) with inoperable forms of LA BC, which was performed 
as a neoadjuvant course ELPCTx.
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According to the integral indicators of quality of life and quality of health between patients in the control and study groups, 
there was no statistically significant difference. In a detailed analysis of the indicators of symptomatic scales, the difference between 
the groups did not exceed the critical. Based on the results of a study conducted among patients receiving endolymphatic chemo-
therapy in a neoadjuvant mode, the subjective evaluations of treatment in absolute numbers have better reference values without 
statistical superiority.
The study of the integrative indicator of quality of life and its discrete elements is an ergonomic and economical means of 
heuristic assessment of the health of patients in order to further develop more rational and convenient ways of solving urgent issues 
of modern oncology by increasing compliance and finding a compromise between the physician and the patient.
Keywords: locally advanced breast cancer, complex treatment, endolymphatic polychemotherapy, systemic polychemother-
apy, quality of life.
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1. Introduction
Over the past decades, according to the registers of most countries of the world, breast 
cancer (BC) is the most widespread cancer and one of the most common causes of disability and 
mortality among women in the world. [1] As part of the development of the etiological profile for 
this pathology, a fairly wide range of factors has been formed, none of which has a statistically 
significant advantage over others, so each particular situation requires an individual approach to 
diagnosis. On the other hand, according to the pathogenetic and morphological characteristics of 
the breast cancer group, a wide variation of neoplasms, different from genotypic and phenotypic 
properties, is combined [2]. According to WHO, in the epidemiological mapping there is a clear 
tendency to a high prevalence among the population of the Western world, which is a consequence 
of their cultural-traditional and socio-demographic characteristics [3]. All this explains the in-
creased costs of maintaining and improving diagnostic and therapeutic measures by public and 
private insurance institutions and the fairness of growing clinical and academic interest in under-
standing the key aspects of breast cancer [4, 5].
A weighted approach to each individual disease dictates to consider it through an individual 
prism for the optimal choice of appropriate therapy. In this very perspective, in cancer practice, 
targeted therapy in the widest possible sense of the term looks: from vector and monoclonal bio-
engineering developments to direct mechanical targeting of necessary substances to the problem 
area by enriching the afferent vascular bed with active components of the drug. The most suitable 
for this method for obvious reasons are locally advanced forms of tumors, and in the context of the 
article, breast cancer (LA BC) [6, 7]. Despite the increasing interest of professionals and amateurs 
in addressing the problem of targeting this cancer, a wide range of treatments suggests that there 
is no statistically validated treatment for each individual case. The local problem of our country 
is a multicausal stagnation in the direction of conducting necessary research and accumulation of 
relevant information [8, 9].
The problem of finding an adequate route for delivery of chemotherapeutic agents and the 
composition of the drug panel itself for the selective complex treatment of LA BC is a topical issue, 
given the poor performance of systemic polychemotherapy (SPCTx).
Regular methods of CTx (intraarterial, intravenous, endolymphatic) are one of the modern 
surgical ways of solving the question of a selective approach to the treatment of malignant neo-
plasms. Lymphotropic therapy is based on the notion of the additivity of the lymphatic structure 
of a particular region with a clear direction of lymph movement from the periphery to the regional 
centres. The complicated and histo toxic method of intradermal injection with subsequent passive 
drainage on the principle of diffusion requires a combination of parallel intravenous administration 
and eliminates repeat CTx sessions. Therefore, the new and progressive stage of the evolution of 
the method was the manoeuvre of microsurgical high-precision catheterization of several major 
lymphatic vessels with saturation of the afferent bed of the target area for 3–5 days. The theoretical 
efficiency and reliability of endolymphatic infusion make the technique promising in the context of 
further study [10, 11]. The aim is to achieve common results for all targeting methods: increasing 
local exposure and reducing the systemic toxic response.
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2. Aim of the research
To compare the indicators of the integrated assessment of the quality of life of patients to lo-
cally advanced forms of breast cancer (LA BC) before and after systemic intravenous polychemo-
therapy (SPCTx) and selective endolymphatic polychemotherapy (ELPCTx) in a neoadjuvant mode. 
3. Materials and methods
The study was conducted on the basis of a random analysis of outpatient cards from 112 pa-
tients with LA BC T4A-DN0-3M0 who received a comprehensive antitumor treatment on the basis 
of the Donetsk regional antitumor center and the University Clinic of the Odessa National Medical 
University from 2000 to 2017, which was proposed a questionnaire at various stages of preoperative 
treatment. Before entering the patient in the study protocol, a written voluntary consent to partic-
ipate in the study was obtained in accordance with the WMA Declaration of Helsinki – Ethical 
principles for medical research involving human subjects, 2013 form.
The sample was standardized according to age, gender, social and clinical parameters. Age 
range: 46.3±12.4 years. Out of all patients, 85 (76 %) belonged to the active working age group. 
The first (control) group consisted of 65 patients (58 %) with inoperable forms of LA BC, which 
was performed in neoadjuvant mode by SPCTx. The second (study group) included 47 patients 
(42 %) with inoperable forms of LA BC, which was performed as a neoadjuvant course ELPCTx. 
The number of courses spent on preoperative PCTx was at most 4. The ultimate goal was to achieve 
the tumour of the operable state.
The study of the quality of life of patients was conducted within the framework of the 
International protocol of the European organization for the study and treatment of cancer, using 
questionnaires for the European organization for the research and treatment of cancer (EORTC 
QLQ-C30) questionnaire, which have been tested in numerous foreign studies and meet the criteria 
for reliability, validity and effectiveness.
The questionnaire has a protocol form and includes 30 standard questions: general questions 
(quality of life (QL) and quality of health (QH)), functional status scale (physical, emotional, role, 
social and cognitive) and the scale of key symptoms. In contrast to the proposed by the authors 
method of the evaluation, a linear analogue scale with a range from 1 to 100 points was applied. 
For functional scales, the worst indicator corresponded to an estimate of 0 points, the best one was 
100 points. In the symptomatic scales, the weakest manifestation was estimated at 0 points, the 
strongest – 100 points.
Patient questionnaires were carried out within 1 week prior to the start of PCTx and 
10–14 days after each course of PCTx. The most representative changes in functional and symp-
tomatic scales occurred at these checkpoints. The questionnaire was conducted among 100 % of 
patients before the start of treatment and stopped after the end of therapy for any reason or at the 
patient’s own request.
Total course doses of chemotherapy were calculated individually for each patient according 
to BSA criteria (Table 1).
Table 1
Protocols for conducting PCTx in the ELPCTx mode according to BSA criteria
CAF protocol:
Cyclophosphamide: from the second to the fourth day – 400 mg/m2; 
Fluorouracil: from the second to the fourth day – 500 mg/m2; 
Doxorubicin: on the first day IV – 50 mg/m2.
CAМF protocol:
Cyclophosphamide: from the second to the fourth day – 400 mg/m2;  
Methotrexate: the first and fifth days – 30 mg/m2; 
Fluorouracil: from the second to the fourth day – 500 mg/m2. 
Doxorubicin: on the first day IV – 30 mg/m2.
CMF protocol:
Cyclophosphamide: from the second to the fourth day – 400 mg/m2;  
Methotrexate: the first and fifth days – 30 mg/m2; 
Fluorouracil: from the second to the fourth day – 500 mg/m2.
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Data processing was performed using standard statistical functions of the MSExcel 
program. When comparing the indicators of QL in the study groups, a nonparametric in-
dex is used – the Pearson coefficient χ2, for the study of dynamics - the indices of the study 
of dynamic series. Static comparison parameters: estimated value of degree of freedom=1; 
at p-level<0.05 χ2=3.841; at p<0.01 χ2=6.635).
5. Results
The general condition of patients at all stages is mainly formed due to objective (presence 
of tumour neoplasms, intoxication syndrome, asthenic syndrome, local and systemic manifesta-
tions of tumour lysis, the addition of secondary infection of compromised tissues) and subjective 
(psychological and emotional discomfort from physical condition, social disadaptation through 
oncological stigmatization and disability) of factors.
After analyzing the QL index (Fig. 1), there were no statistically significant differences 
in the control group: the mean value was 54±11.3 points in the control group, 57±4.1 points in 
the study (at p=0.67 index=0.182). After completing 1 and 2 courses of chemotherapy, the QL 
index had a phase-out negative dynamics of the first (7.4 % and 8.0 %, respectively, with a final 
result of 46±4.3 points), and in the second (5.3 % and 13.0 %, respectively, with a final result of 
47±3.1 points) in groups, retaining proportional statistical closeness of results. It is worth noting 
that because of the expressed intoxication syndrome and the psychological discomfort of partici-
pating in the trial, 3 patients (4.6 %) of group 1 and 2 patients (4.3 %) of the second group refused 
to further study their quality of life and continued treatment in the usual way. Such dynamics of 
indicators, according to the authors, is related to insufficiently established complications with pa-
tients and insufficient explanation of the essence of treatment: the persistence of the intoxication 
syndrome, the dissonance of the expected and actual changes in tumour size, the panic disappoint-
ment of treatment and the lack of improvement in well-being were interpreted by most patients as 
a negative result . The ultimate aim was achieved in 16 (25 %) patients in the first group and in 
13 (28 %) patients in the second group. After completing the third course of chemotherapy, the ref-
erence values of the QL parameter were positive, increasing by 13 % (52±2.3 points) in the control 
group and by 18 % (55±4.9 points) in the study groups as a consequence of improving the general 
condition, becoming accustomed to the systematic wave-like dynamics of the symptoms toxicity 
to PCTx, improvement of local tumour status and achievement of the end result in most patients. 
However, statistically, the indices of both groups remained indispensable (at p=0.671, the index 
χ2=0.181). The regimen of the tumour was achieved in 30 (46 %) women in the first group and in 
21 (45 %) women in the second group. After completion of 4 courses of PCTx, the indicators de-
creased by two or four points in both groups (50±4.4 and 52±2.3 points respectively), interpreted as 
the result of physical and moral deprivation of patients, lack of the same dynamics of clinical symp-
toms as in other patients, depression in the positive result and dissatisfaction with the symptoms of 
iatrogenic intoxication. There was no statistical difference in favour of one or another technique in 
the fact of holding 4 courses of PCTx (χ2=0.08 at p=0.778). Clinical effects appeared in 17 (26 %) 
women in the control group and in 11 (23 %) women in the study group. Unfortunately, the resect-
able state of La BC did not reach 2 (3 %) patients of the first group and 2 patients (4 %) of the second 
group; They were offered a system of professional assistance and support for cancer patients and 
symptomatic therapy in an oncologic dispensary.
Another indicator of the general character – the quality of health (Fig. 2) – was similar dy-
namics. Prior to conducting PCTx in patients of the first and second groups, the following results 
were obtained: the average score of good health in group 1 was 32±4.1 points, and in the sec-
ond – 35±3.7 points, which had no statistically significant difference (χ2=0.202, p=0.654 ) Accord-
ing to patients, such a low estimate is due to the effect of the “depressed” state due to “incurable” 
disease and pessimistic predictions about the results of future treatment, formed through self-dis-
information of patients when communicating with each other and studying unverified sources. 
Unfortunately, the conditions and format of the experiment did not allow a cleaner study to isolate 
patients and clarify their health and technical options for treating this pathology. Subsequently, 
after each course of chemotherapy, there was a stable difference of 3, 3 and 2 points, respectively, 
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insignificant by the Pearson coefficient (χ2<3.841), and with the fluctuations within the group of 
5±1 %, between the groups of indicators. In the phase of neoadjuvant therapy, the patient had no 
to evaluate the final result, however, with the help of explanatory work the doctor can correctly in-
terpret the trends of the general state of the organism and local parameters (size and disintegration 
of the tumour). 
Fig. 1. QL patients before and after SPCTx and ELPCTx
Fig. 2. QH patients before and after SPCTx and ELPCTx
In the structure of the questionnaire EORTC QLQ-C30, specific questions of the symp-
tomatic scale are first and foremost, there are placed more general scales of functional, cognitive, 
emotional, psychological and social status, at the end there are two integral indicators – quality of 
life and quality of health, giving patients the opportunity move from solving more simple tasks to 
responding to global additive issues. Analyzing the questionnaires in reverse order, you can evalu-
ate the components of these integral parameters.
The following changes were observed in the analysis of indicators on the general and physi-
cal health scales (Fig. 3, 4): a statistically insignificant difference before the start of chemotherapy 
(63±6.4 and 81±5.4 points in the first group, 65±4.3 and 83±9.6 points in the second, χ2, respective-
ly, 0.087 and 0.136), followed by a negative dynamics of 5 points after 2 courses of chemotherapy 
and almost unchanged at the time of further treatment.
The smallest changes in response to chemotherapy were observed for the indicator of cog-
nitive status: the intergroup and intragroup incomplete differentials stood in the range of 4 points 
and did not have statistical differences (Fig. 5).
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Fig. 3. The general condition of patients before and after the SPCTx and ELPCTx
Fig. 4. Physical condition of patients before and after the SPCTx and ELPCTx
The most variability was naturally found in the results on the scales of psychological and 
emotional state and social adaptation. As expected, the indicators of the emotional background 
were extremely labile and the dynamics of the system was not traced; of course, this parameter is 
the most subjective and least reliable for discrete evaluation, however, as already noted, necessary 
for an integrated approach. During the analysis of the psychological state of women in both groups 
before and during the PCTx, fluctuations of wide amplitude that were not related to external factors 
(Fig. 6) were revealed, which is a serious consequence of insufficient professional psychotherapeu-
tic assistance to patients.
On the other hand, the scale of social adaptation has shown a non-slip positive dynamics for 
both groups, though, again, without statistical discrepancies with intergroup differences of 5 points 
maximum. Yet, according to the authors, this parameter is a key component of the quality of life 
indicator, since it is social adaptation and self-determination that is the ultimate goal of integrated 
treatment and an intermediate for each of the stages.
Before the start of chemotherapy, the patients of both groups considered themselves equal-
ly low socially adapted (47±3.7 points in the first group and 49±3.9 in the second group). After 
two courses of PCTx in both groups, the indicators improved: 25.5 % in control patients, making 
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59±7.2 points, and by 16 % in the studied cohort with 49±4.3 points. Subsequently, the positive 
dynamics were maintained (Fig. 7): in the first group +8.5 % (64±5.0 points) after 3 courses 
and +12.5 % (72±5.2 points) after the fourth; in the second – +11 % (65±4.7 points) in the third stage 
of the study +7.5 % (72±3.1 points) in the fourth. At the same time, objectively, in patients, there 
was a marked reduction of local symptoms in both cohorts of patients.
Fig. 5. Cognitive condition of patients before and after the SPCTx and ELPCTx
Fig. 6. Emotional condition of patients before and after the SPCTx and ELPCTx
Fig. 7. Social condition of patients before and after the SPCTx and ELPCTx
During the analysis of the panel of symptomatic scales for publication only indicators with 
high reference values, statistically significant differences, and pathogenetic connection with the 
intervention: pain, nausea and loss of appetite – as parameters characterizing local and systemic 
changes in the body.
The intoxication syndrome is a major side effect of chemotherapeutic treatment. It is worth 
noting that objectively the symptoms of intoxication persist on average 5±1 day after SPCTx and 
88 89 90
89
89 91 91
92
Before the
beginning
After 2 courses After 3 courses After 4 courses
1 group 2 group
83
67
91 82
77 84 73 87
Before the
beginning
After 2 courses After 3 courses After 4 courses
1 group 2 group
47 59
64
7249
57
65
72
Before the
beginning
After 2 courses After 3 courses After 4 courses
1 group 2 group
Original Research Article:
full paper
(2018), «EUREKA: Health Sciences»
Number 4
10
Medicine and Dentistry
4±1 day after ELPCTx. It is also important that the intoxication syndrome is generated both by the 
presence of the tumour itself and by therapeutic measures. It is advisable to explain this fact in 
detail to patients before conducting chemotherapy and to teach them to track the dynamics of new 
symptoms for a proper interpretation of their own condition.
The search for new drugs and their rational combination contribute to the reduction of the 
symptoms of iatrogenic poisoning of the body, regardless of the route of administration of drugs, 
therefore, the incidence of insomnia, apathy, depression and general fatigue will not change signifi-
cantly. However, as can be seen from Fig. 8, 9, nausea and loss of appetite are observed in many 
patients with lysis syndrome before the treatment, which on average gives a low score (13±1.4 and 
11±0.9 points respectively in the first group, 13±1.9 and 11±1.1 – in the second). At later stages, 
these symptoms were noted in typical terms in general, and were evaluated respectively [64±4.3 
and 62±1.3] points in the first group and [59±4.1 and 63±2.0] points in the second to the second 
stage, [58±5.3 i57±1.1] and [57±3.2i59±1.7], respectively, on the third; [49±5.7 i51±1.3] and [49±4.0 
and 49±2.1] in the fourth. The analysis did not reveal a significant difference between the parame-
ters at any of the stages.
Fig. 8. Nausea of patients before and after the SPCTx and ELPCTx
Fig. 9. Loss of appetite of patients before and after the SPCTx and ELPCTx
Separately, it is necessary to consider the parameter of pain syndrome. Unlike the others, it 
is an indicator of the dynamics of the local status. Interdependent control groups of reliable differ-
ences are not traced (Fig. 10).
Fig. 10. Pain syndrome in patients before and after the SPCTx and ELPCTx
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6. Discussion
Modern medicine is in the unbalanced conflict environment of the ideas of the past and the 
present. Formed at the beginning of the last century, patterns of thinking and implementation of 
approaches to working with patients were characterized by profound personalization and unreason-
ably radical actions, and now phase-by-stage processes of viewing and comparing are underway 
[11, 12]. With the advent of evidence-based medicine and the beginning of the formation of interna-
tional information bases in the global medical community comes the conclusion about the irratio-
nality of many classical methods of treatment, and the methods used to assess the results achieved 
[13]. However, despite the constant progress of medicine, new advances in the development of gen-
eral and special directions, as well as the tireless and close attention of the public to the problems 
of medicine, statistical data on a scale of decades do not show convincing qualitative changes in 
the dynamics of morbidity and mortality [14, 15]. A rational approach to the organization of work 
posits that the achievement of the absolute result is a strategically false course, and a competent 
program of development envisages, first of all, the right choice of purpose and the correct statement 
of the problem before discipline in the person of each individual participant. Therefore, at the end 
of the last century, medicine completely changed the concept of its approach to the patient, turning 
it from the object to the subject of the medical process. The aim of achieving maximum clinical 
effect at the cost of limiting comfort was no longer a self-image, and the new balanced way of 
medicine became patient oriented, on its needs, interests and experiences [16]. The total vector of 
human impact in the health care system has changed the direction from quantitative intensive and 
extensive statistical indicators of overall survival, duration of a non-recurrent period and disability 
to compromise qualitative indicators of comfort and health. In this context, the question arises of 
the need to develop and use measures to evaluate not only the quantitative but also qualitative com-
ponent of a comprehensive conclusion on the results of therapy. Therefore, an important indicator 
to be taken into account is the quality of life of a patient [17, 18].
In the original IndexMedicus (1977), QL is defined as the physical, emotional, financial and 
spiritual well-being of man [19]. According to the decision of the American Society of Clinical 
Oncology (ASCO), QL is more important than the level of non-recurrent survival in assessing the 
results of antitumor therapy [20].
The main advantage of the QL index is its integrative ability: the ideal QL index is an 
objective assessment of subjective data. In the future it will provide an opportunity to unite and 
coordinate a number of nonparametric additive characteristics such as overall health, emotional, 
cognitive, psychological and social aspects, i.e. implementing strategic objective to assess the 
condition of the patient before and after treatment in terms of the patient, then it will become 
possible to rationalize further therapeutic tactics more effectively. The main drawback of the QL 
index is idempotence its synthetic nature and lack immanence parameters, which create prereq-
uisites for the approximability of any mathematical function for its modelling and quantitative 
and qualitative terms.
Modern integrated assessment questionnaire QL reflect these positive and negative aspects, 
but still allow you to “compare what is comparable.” The widespread introduction of standardized 
forms surveys as a routine cancer research and regular large-scale meta-analyzes will accumulate 
and structure the material to further a more advanced scientific and methodological materials.
Using the EORTC QLQ-C30 questionnaire as one of the most common forms in our 
research is largely dictated by these considerations. In the future, the systematization of the 
data of each individual medical unit will create the opportunity to form the axis of academic 
and clinical experience in a particular direction and develop an effective system of vertical and 
horizontal feedback on the local, regional, state and international levels. Taking into account 
the difference in the structure of patterns of health care organization between the countries of 
Eastern and Western Europe, as well as their greater practice in the study of quality of life in-
dicators in the framework of an expanded individual approach to patient treatment, it is prom-
ising to create national information bases on discrete issues with further versatile comparisons 
and definitions of the most competitive options in the context of the evolution of methods and 
their artificial selection.
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The quality of life study as an indicator is not a competitor to classical methods for evalu-
ating the quality of treatment and can not be considered an alternative to extensive and intensive 
statistical parameters. However, parallel study of objective and subjective treatment outcomes al-
lows using the second as a tuning cart the adequate effectiveness of the patient care program and 
facilitates the process of understanding between the physician and the patient, allowing the latter 
to actively participate in their own treatment. Investigating the correlation between clinical, mor-
phological, laboratory and instrumental effects of intervention and a comprehensive indicator of 
patient’s quality of life will take place in the future.
7. Conclusions
1. After the study identified beyond the range of quality of life in patients with inoperable 
form of LA BC before and after neoadjuvant systemic chemotherapy courses (SPCTx) and endo-
lymphatic polychemotherapy (ELPCTx).
2. Clarified value including assessment of quality of life to the complex characteristics of the 
final treatment results, allowing to accumulate experience and information in this area and increase 
the practical sense of scientific work.
3. Research the integrative quality of life and its discrete elements are ergonomic and eco-
nomical means of heuristic evaluation of the health status of patients to further develop the most 
efficient and convenient way to address pressing issues of modern oncology by improving compli-
ance and compromise between doctor and patient.
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Abstract
We have investigated the efficacy of pulse-therapy with glucocorticoids (GC) at different time stages (in debuts, at the 
recurrent stage and at the stage of progression) of secondary progressive course (SPC) of multiple sclerosis (MS) in 70 patients 
(57 women and 13 men) at the ages from 28 to 67 years (mean age 45±2.5 years). The duration of the disease accounted for 7 up to 
34 years (average duration was 19.8±2.3 years). We have conducted 438 courses of GC therapy: at the onsets – 11, at the recurrent 
stage (RS) – 178 and at the stage of secondary progression-249.
The efficacy of hormonal therapy was assessed taking into account the following criteria: the dynamics of regression of 
neurological symptoms under the influence of the first course of GC therapy at the stage of onsets; a comparative evaluation of re-
mission’s duration after admission and without taking GC at the onsets; duration of RS depending on the duration of remissions after 
the first course of GC therapy; a comparative evaluation of remissions’ duration after the 1st (at the stage of onset and/or on the RS), 
and the period of stabilization on the SPS before the last courses of GC; the variants of secondary progression under the influence of 
GC courses; scores according the EDSS disability scale after the 1st and before the last course of GC therapy; the rate of progression 
under the influence of the repeated courses of GC therapy.
We have defined the three categories of efficacy at the repeated courses of pulse therapy with GC: the moderate efficacy, the 
low efficacy, the lack of efficacy. We have not observed the high efficacy in patients with SPC.
The patients with MFR <1.0, among which the pulse therapy with GC promoted the prolongation of RS, relieved the severe 
(less often) and moderate (more often) relapses, the outcome of which was accompanied by a moderate and stable neurologic deficit, 
were subsumed under the subgroup with moderate efficacy (21 individuals). The most favorable progressive variant of progression 
prevailed in these patients after transformation of RS into SPS.
The patients with different rate of MFR (9 – with MFR <1.0 and 12 – with MFR>1.0), with short (more often) and moderate 
(less often) RS, during which the accumulation of neurological deficit due to the frequent and heavy relapses had occurred, were sub-
sumed under the subgroup with low efficiency (21 individuals). After transformation into SPS, the recurrent variant of progression 
prevailed in these patients.
The patients who were characterized by short RS, by predominance of severe and prolonged relapses, the MFR value 
greater than 1.0, the steady accumulation of a pronounced and persistent neurologic deficit, a high rate of progression and high 
scores on the EDSS disability scale more than 6.5 points) were subsumed under the subgroup with the lack of efficacy (28 indi-
viduals). After transformation in the SPC, the most unfavorable variant of progression prevailed (21 patients); significantly less 
frequent were the recurrent (5 patients) and a combination of a steady and recurrent (2 patients) progression. The persistent lack 
of efficacy of the hormonal therapy in this subgroup of patients was most likely associated with the genetically determined low 
individual sensitivity to GC.
